Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Qlosi (CSF-1) in Presbyopia
NCT05393895Phase 3Completed
- Sponsor
- Orasis Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of artemether + lumefantrine in presbyopia (2 arms), sponsored by Orasis Pharmaceuticals. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 21 weeks. Started Apr 2022; status: completed.
02
Drugs
artemether + lumefantrine
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT05393895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05393895.